Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for RLAY

Stock Name	Relay Therapeutics Inc
Ticker	RLAY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75943R1023

Show aggregate RLAY holdings

News associated with RLAY

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.25 Consensus PT from Analysts: Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the […] - 2025-08-27 02:54:54
XTX Topco Ltd Purchases 20,161 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): XTX Topco Ltd lifted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 33.7% in the 1st quarter, HoldingsChannel.com reports. The fund owned 79,913 shares of the company’s stock after buying an additional 20,161 shares during the period. XTX Topco Ltd’s holdings in Relay Therapeutics were worth $209,000 as of its most recent […] - 2025-08-14 04:22:55
Raymond James Financial Has Lowered Expectations for Relay Therapeutics (NASDAQ:RLAY) Stock Price: Relay Therapeutics (NASDAQ:RLAY – Free Report) had its target price reduced by Raymond James Financial from $29.00 to $19.00 in a research report report published on Friday morning,Benzinga reports. Raymond James Financial currently has a strong-buy rating on the stock. RLAY has been the subject of several other research reports. Wells Fargo & Company started […] - 2025-08-11 03:50:57
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have been given an average rating of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year […] - 2025-07-30 02:46:52
Relay Therapeutics (NASDAQ:RLAY) versus Incannex Healthcare (NASDAQ:IXHL) Head-To-Head Review: Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 0.4% of Incannex […] - 2025-07-29 02:49:02
DekaBank Deutsche Girozentrale Buys 8,937 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): DekaBank Deutsche Girozentrale boosted its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 14.9% during the 1st quarter, HoldingsChannel reports. The fund owned 68,937 shares of the company’s stock after purchasing an additional 8,937 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Relay Therapeutics were worth $181,000 at the end […] - 2025-07-15 06:23:59
Analysts Set Relay Therapeutics, Inc. (NASDAQ:RLAY) Target Price at $17.67: Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The […] - 2025-07-08 02:38:55
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Average Price Target from Analysts: Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month […] - 2025-06-13 02:32:49
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Holdings Boosted by Squarepoint Ops LLC: Squarepoint Ops LLC boosted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 535.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 162,588 shares of the company’s stock after purchasing an additional 137,020 shares during the quarter. Squarepoint Ops […] - 2025-06-03 05:38:55
Northern Trust Corp Raises Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY): Northern Trust Corp boosted its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 24.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,169,979 shares of the company’s stock after acquiring an additional 231,713 shares during the quarter. Northern Trust Corp’s holdings in Relay Therapeutics were worth $4,820,000 at the […] - 2025-05-22 04:22:54
Graham Capital Management L.P. Acquires New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY): Graham Capital Management L.P. acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 31,569 shares of the company’s stock, valued at approximately $130,000. A number of other large investors have also added to […] - 2025-05-20 05:10:52
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Average PT from Brokerages: Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month price target […] - 2025-05-19 02:30:55
MetLife Investment Management LLC Acquires 16,477 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): MetLife Investment Management LLC increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 28.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 74,166 shares of the company’s stock after buying an additional 16,477 shares during the quarter. MetLife Investment Management LLC’s holdings in Relay Therapeutics were worth $306,000 […] - 2025-05-08 04:56:55
189,046 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by Raymond James Financial Inc.: Raymond James Financial Inc. acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 189,046 shares of the company’s stock, valued at approximately $779,000. Other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its position in shares […] - 2025-05-07 05:46:50
Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Reduced by Wells Fargo & Company MN: Wells Fargo & Company MN trimmed its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 45.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 71,425 shares of the company’s stock after selling 59,042 shares during the period. Wells Fargo & Company MN’s holdings in Relay Therapeutics were worth $294,000 as of […] - 2025-05-07 04:52:58
Renaissance Technologies LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY): Renaissance Technologies LLC grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 130.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,549,190 shares of the company’s stock after buying an additional 878,095 shares during the […] - 2025-04-20 05:00:52
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. (NASDAQ:RLAY): JPMorgan Chase & Co. decreased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,978,443 shares of the company’s stock after selling 539,073 shares during the period. JPMorgan Chase & […] - 2025-04-11 06:20:51
American Century Companies Inc. Purchases 51,499 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): American Century Companies Inc. increased its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 23.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 272,166 shares of the company’s stock after buying an additional 51,499 shares during the quarter. American Century Companies Inc.’s holdings in Relay Therapeutics were worth $1,121,000 at the […] - 2025-04-11 04:34:48
Prudential Financial Inc. Buys 173,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): Prudential Financial Inc. grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 45.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 549,645 shares of the company’s stock after acquiring an additional 173,000 shares during the quarter. Prudential Financial […] - 2025-04-04 04:37:00
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Teacher Retirement System of Texas: Teacher Retirement System of Texas grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 19.5% in the fourth quarter, Holdings Channel reports. The fund owned 33,720 shares of the company’s stock after purchasing an additional 5,492 shares during the period. Teacher Retirement System of Texas’ holdings in Relay Therapeutics were worth $139,000 […] - 2025-04-03 04:54:50
Cibc World Markets Corp Buys New Position in Relay Therapeutics, Inc. (NASDAQ:RLAY): Cibc World Markets Corp purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,388 shares of the company’s stock, valued at approximately $47,000. Several other large investors also recently bought and […] - 2025-03-28 06:18:47
Bank of New York Mellon Corp Purchases 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): Bank of New York Mellon Corp raised its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 18.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 328,897 shares of the company’s stock after acquiring an additional 50,190 shares […] - 2025-03-24 05:10:52
Relay Therapeutics (NASDAQ:RLAY) vs. Kyverna Therapeutics (NASDAQ:KYTX) Financial Survey: Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends. Insider & Institutional Ownership 18.1% of Kyverna […] - 2025-03-21 03:51:04
Los Angeles Capital Management LLC Acquires 20,880 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY): Los Angeles Capital Management LLC increased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 65.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,770 shares of the company’s stock after purchasing an additional 20,880 shares during the period. […] - 2025-03-05 08:41:42
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by China Universal Asset Management Co. Ltd.: China Universal Asset Management Co. Ltd. raised its position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 37.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,491 shares of the company’s stock after purchasing an additional 9,740 shares […] - 2025-02-04 06:53:08

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc RLAY holdings

Date	Number of RLAY Shares Held	Base Market Value of RLAY Shares	Local Market Value of RLAY Shares	Change in RLAY Shares Held	Change in RLAY Base Value	Current Price per RLAY Share Held	Previous Price per RLAY Share Held
2025-09-26 (Friday)	66,868	USD 345,708	USD 345,708
2025-09-25 (Thursday)	66,868	USD 292,882	USD 292,882	0	USD -9,361	USD 4.38	USD 4.51999
2025-09-24 (Wednesday)	66,868	USD 302,243	USD 302,243
2025-09-17 (Wednesday)	66,434	USD 271,715	USD 271,715	0	USD -2,657	USD 4.09	USD 4.12999
2025-09-16 (Tuesday)	66,434	USD 274,372	USD 274,372
2025-09-12 (Friday)	66,000	USD 263,340	USD 263,340
2025-09-11 (Thursday)	66,000	USD 271,920	USD 271,920	868	USD 7,484	USD 4.12	USD 4.06

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RLAY by Blackrock for IE00B3VWM098

Show aggregate share trades of RLAY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-09-11 BUY 868 4.120* 3.76
2025-08-21 SELL -217 3.410* 3.77 Profit of 817 on sale
2025-07-31 BUY 651 3.520* 3.77
2025-06-30 SELL -434 3.460* 3.79 Profit of 1,645 on sale
2025-06-25 SELL -217 3.260* 3.80 Profit of 825 on sale
2025-06-20 SELL -434 3.190* 3.81 Profit of 1,654 on sale
2025-05-23 BUY 217 2.910* 3.91
2025-05-19 SELL -217 2.930* 3.95 Profit of 857 on sale
2025-05-15 SELL -651 2.790* 3.97 Profit of 2,583 on sale
2025-05-12 SELL -217 3.110* 4.00 Profit of 867 on sale
2025-05-09 SELL -217 3.000* 4.00 Profit of 869 on sale
2025-04-30 SELL -217 3.330* 4.06 Profit of 881 on sale
2025-04-24 SELL -434 3.190* 4.09 Profit of 1,777 on sale
2025-04-17 SELL -217 2.690* 4.16 Profit of 903 on sale
2025-04-15 SELL -651 2.760* 4.19 Profit of 2,730 on sale
2025-04-14 SELL -651 2.570* 4.21 Profit of 2,741 on sale
2025-04-09 SELL -868 2.300* 4.27 Profit of 3,710 on sale
2025-04-07 SELL -1,519 2.050* 4.33 Profit of 6,572 on sale
2025-04-04 SELL -2,170 2.000* 4.35 Profit of 9,447 on sale
2025-03-31 BUY 217 2.620* 4.42
2025-03-19 SELL -434 3.340* 4.57 Profit of 1,982 on sale
2025-03-14 SELL -1,308 3.660* 4.61 Profit of 6,033 on sale
2025-03-13 SELL -436 3.410* 4.63 Profit of 2,018 on sale
2025-03-12 SELL -7,412 3.660* 4.64 Profit of 34,412 on sale
2025-03-07 SELL -436 3.460* 4.70 Profit of 2,049 on sale
2025-03-06 SELL -654 3.480* 4.72 Profit of 3,085 on sale
2025-03-03 SELL -218 3.200* 4.79 Profit of 1,043 on sale
2025-02-28 SELL -1,308 3.410* 4.81 Profit of 6,289 on sale
2025-02-26 SELL -218 3.750* 4.85 Profit of 1,058 on sale
2025-02-25 SELL -654 3.680* 4.87 Profit of 3,186 on sale
2025-02-18 BUY 1,090 3.920* 4.97
2025-02-13 BUY 218 3.960* 5.03
2025-02-12 BUY 218 3.760* 5.05
2025-02-11 BUY 654 3.740* 5.08
2025-02-06 BUY 1,962 4.510* 5.14
2025-01-27 BUY 218 4.720* 5.25
2024-12-30 BUY 1,090 4.180* 5.34
2024-12-06 BUY 872 4.610* 5.41
2024-12-05 BUY 218 4.280* 5.45
2024-12-04 BUY 1,090 4.390* 5.49
2024-11-29 BUY 1,090 4.700* 5.60
2024-11-27 BUY 872 4.800* 5.67
2024-11-26 BUY 218 4.760* 5.71
2024-11-25 BUY 24,603 4.860* 5.75
2024-11-21 BUY 715 4.640* 5.86
2024-11-20 BUY 429 4.660* 5.93
2024-11-18 BUY 1,716 4.890* 6.07
2024-11-12 BUY 1,144 5.940* 6.07
2024-11-08 BUY 710 6.200* 6.06
2024-11-07 BUY 2,130 6.140* 6.06
2024-11-06 BUY 284 6.250* 6.04
2024-10-31 BUY 142 5.635* 6.15
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-09-11	BUY	868	4.120*	3.76
2025-08-21	SELL	-217	3.410*	3.77 Profit of 817 on sale
2025-07-31	BUY	651	3.520*	3.77
2025-06-30	SELL	-434	3.460*	3.79 Profit of 1,645 on sale
2025-06-25	SELL	-217	3.260*	3.80 Profit of 825 on sale
2025-06-20	SELL	-434	3.190*	3.81 Profit of 1,654 on sale
2025-05-23	BUY	217	2.910*	3.91
2025-05-19	SELL	-217	2.930*	3.95 Profit of 857 on sale
2025-05-15	SELL	-651	2.790*	3.97 Profit of 2,583 on sale
2025-05-12	SELL	-217	3.110*	4.00 Profit of 867 on sale
2025-05-09	SELL	-217	3.000*	4.00 Profit of 869 on sale
2025-04-30	SELL	-217	3.330*	4.06 Profit of 881 on sale
2025-04-24	SELL	-434	3.190*	4.09 Profit of 1,777 on sale
2025-04-17	SELL	-217	2.690*	4.16 Profit of 903 on sale
2025-04-15	SELL	-651	2.760*	4.19 Profit of 2,730 on sale
2025-04-14	SELL	-651	2.570*	4.21 Profit of 2,741 on sale
2025-04-09	SELL	-868	2.300*	4.27 Profit of 3,710 on sale
2025-04-07	SELL	-1,519	2.050*	4.33 Profit of 6,572 on sale
2025-04-04	SELL	-2,170	2.000*	4.35 Profit of 9,447 on sale
2025-03-31	BUY	217	2.620*	4.42
2025-03-19	SELL	-434	3.340*	4.57 Profit of 1,982 on sale
2025-03-14	SELL	-1,308	3.660*	4.61 Profit of 6,033 on sale
2025-03-13	SELL	-436	3.410*	4.63 Profit of 2,018 on sale
2025-03-12	SELL	-7,412	3.660*	4.64 Profit of 34,412 on sale
2025-03-07	SELL	-436	3.460*	4.70 Profit of 2,049 on sale
2025-03-06	SELL	-654	3.480*	4.72 Profit of 3,085 on sale
2025-03-03	SELL	-218	3.200*	4.79 Profit of 1,043 on sale
2025-02-28	SELL	-1,308	3.410*	4.81 Profit of 6,289 on sale
2025-02-26	SELL	-218	3.750*	4.85 Profit of 1,058 on sale
2025-02-25	SELL	-654	3.680*	4.87 Profit of 3,186 on sale
2025-02-18	BUY	1,090	3.920*	4.97
2025-02-13	BUY	218	3.960*	5.03
2025-02-12	BUY	218	3.760*	5.05
2025-02-11	BUY	654	3.740*	5.08
2025-02-06	BUY	1,962	4.510*	5.14
2025-01-27	BUY	218	4.720*	5.25
2024-12-30	BUY	1,090	4.180*	5.34
2024-12-06	BUY	872	4.610*	5.41
2024-12-05	BUY	218	4.280*	5.45
2024-12-04	BUY	1,090	4.390*	5.49
2024-11-29	BUY	1,090	4.700*	5.60
2024-11-27	BUY	872	4.800*	5.67
2024-11-26	BUY	218	4.760*	5.71
2024-11-25	BUY	24,603	4.860*	5.75
2024-11-21	BUY	715	4.640*	5.86
2024-11-20	BUY	429	4.660*	5.93
2024-11-18	BUY	1,716	4.890*	6.07
2024-11-12	BUY	1,144	5.940*	6.07
2024-11-08	BUY	710	6.200*	6.06
2024-11-07	BUY	2,130	6.140*	6.06
2024-11-06	BUY	284	6.250*	6.04
2024-10-31	BUY	142	5.635*	6.15

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RLAY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	144,620	1,200	397,051	36.4%
2025-09-18	380,192	4,620	1,109,349	34.3%
2025-09-17	128,405	1,740	456,014	28.2%
2025-09-16	96,003	8,039	417,266	23.0%
2025-09-15	764,733	0	1,088,958	70.2%
2025-09-12	137,163	1,605	418,228	32.8%
2025-09-11	188,124	0	352,285	53.4%
2025-09-10	249,836	0	607,365	41.1%
2025-09-09	167,895	0	300,910	55.8%
2025-09-08	254,941	2,900	448,572	56.8%
2025-09-05	351,688	1,300	645,601	54.5%
2025-09-04	289,712	35,629	726,488	39.9%
2025-09-03	494,561	0	1,086,099	45.5%
2025-09-02	204,564	0	343,174	59.6%
2025-08-29	129,525	0	343,959	37.7%
2025-08-28	159,475	0	314,271	50.7%
2025-08-27	70,508	0	152,821	46.1%
2025-08-26	96,608	0	221,801	43.6%
2025-08-25	78,317	0	174,186	45.0%
2025-08-22	170,944	0	379,008	45.1%
2025-08-21	103,790	0	303,936	34.1%
2025-08-20	185,219	1,931	412,921	44.9%
2025-08-19	184,996	0	365,722	50.6%
2025-08-18	155,717	0	295,322	52.7%
2025-08-15	183,595	177	459,021	40.0%
2025-08-14	230,081	1	595,701	38.6%
2025-08-13	105,029	5	440,976	23.8%
2025-08-12	363,358	0	741,674	49.0%
2025-08-11	225,550	13,820	751,354	30.0%
2025-08-08	1,093,754	46,830	1,874,163	58.4%
2025-08-07	227,486	0	436,978	52.1%
2025-08-06	183,857	45	473,124	38.9%
2025-08-05	102,276	16	324,674	31.5%
2025-08-04	138,014	0	1,074,852	12.8%
2025-08-01	158,963	0	1,364,035	11.7%
2025-07-31	282,708	0	2,038,337	13.9%
2025-07-30	123,973	0	514,807	24.1%
2025-07-29	280,006	2,175	995,074	28.1%
2025-07-28	513,962	1,351	1,169,000	44.0%
2025-07-25	251,136	32	947,123	26.5%
2025-07-24	1,719,273	174	3,236,369	53.1%
2025-07-23	189,149	250	2,686,072	7.0%
2025-07-22	175,994	2,000	857,917	20.5%
2025-07-21	210,138	300	845,244	24.9%
2025-07-18	124,716	157	728,170	17.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE